Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosis
Top Cited Papers
Open Access
- 13 January 2026
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 32 (2) , 553-560
Abstract
Linezolid, an oxazolidinone, is a cornerstone of treatment regimens for highly drug-resistant tuberculosis but cannot be used in drug-susceptible disease because of toxicity. This toxicity results from inhibition of mammalian mitochondrial protein synthesis. Here we show the development of a new oxazolidinone, MK-7762, with antitubercular activity that is better than linezolid and limited mitochondrial protein synthesis inhibition. The cryogenic electron microscopy structure of the stalled mycobacterial ribosome with MK-7762 revealed the basis for this selectivity. BALB/c mouse models of disease showed MK-7762 reduced lung bacterial burden by a 3-log-fold decrease in an acute model ( N = 18) and a 2-log-fold decrease in chronically infected animals ( N = 18). MK-7762 showed lesion penetration similar to linezolid in C3HeB/FeJ mice. MK-7762 had pharmacokinetic properties predicting low once-daily doses in humans and a favorable 14-day preclinical safety profile in Wistar Han rats ( N = 30) and Beagle dogs ( N = 6). Four-month safety studies in both rats ( N = 20) and dogs ( N = 24) showed no changes in hematology parameters at exposures well above the 100-mg predicted human dose. These data will enable MK-7762 to be explored as a component of new tuberculosis treatment combinations for all forms of the disease.Keywords
Funding Information
- Bill and Melinda Gates Foundation (INV-001727)
- Division of Intramural Research (AI000693)
This publication has 34 references indexed in Scilit:
- Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosisTuberculosis, 2012
- A Mycobacterium tuberculosis Sigma Factor Network Responds to Cell-Envelope Damage by the Promising Anti-Mycobacterial ThioridazinePLOS ONE, 2010
- PHENIX: a comprehensive Python-based system for macromolecular structure solutionActa Crystallographica Section D Structural Biology, 2010
- Inhibition of Mammalian Mitochondrial Protein Synthesis by OxazolidinonesAntimicrobial Agents and Chemotherapy, 2006
- Mitochondrial Toxicity Associated with LinezolidNew England Journal of Medicine, 2005
- Preclinical Testing of the Nitroimidazopyran PA-824 for Activity against Mycobacterium tuberculosis in a Series of In Vitro and In Vivo ModelsAntimicrobial Agents and Chemotherapy, 2005
- Coot: model-building tools for molecular graphicsActa Crystallographica Section D Structural Biology, 2004
- The use of microarray analysis to determine the gene expression profiles of Mycobacterium tuberculosis in response to anti-bacterial compoundsTuberculosis, 2004
- Signature Gene Expression Profiles Discriminate between Isoniazid-, Thiolactomycin-, and Triclosan-Treated Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2003
- Directly Observed Therapy, Short-Course: The Best Way to Prevent Multidrug- Resistant TuberculosisChemotherapy, 1999